Disulfiram/copper complex inhibits proliferation and induces apoptosis in hepatocellular carcinoma cells through dephosphorylation and mitochondrial translocation of Drp1
Basic Medicine|更新时间:2026-01-09
|
Disulfiram/copper complex inhibits proliferation and induces apoptosis in hepatocellular carcinoma cells through dephosphorylation and mitochondrial translocation of Drp1
Journal of Third Military Medical UniversityVol. 43, Issue 23, Pages: 2302-2310(2020)
作者机构:
400038 重庆,陆军军医大学(第三军医大学)药学与检验医学系生药学与中药学教研室
作者简介:
基金信息:
the General Program of National Natural Science Foundation of China(31571425)
Jie LI, Jinjiao HU, Xiuxing JIANG, et al. Disulfiram/copper complex inhibits proliferation and induces apoptosis in hepatocellular carcinoma cells through dephosphorylation and mitochondrial translocation of Drp1[J]. Journal of Third Military Medical University, 2020, 43(23): 2302-2310.
DOI:
Jie LI, Jinjiao HU, Xiuxing JIANG, et al. Disulfiram/copper complex inhibits proliferation and induces apoptosis in hepatocellular carcinoma cells through dephosphorylation and mitochondrial translocation of Drp1[J]. Journal of Third Military Medical University, 2020, 43(23): 2302-2310. DOI: 10.16016/j.1000-5404.202007186.
Disulfiram/copper complex inhibits proliferation and induces apoptosis in hepatocellular carcinoma cells through dephosphorylation and mitochondrial translocation of Drp1
To determine the effects of disulfiram/copper complex
copper(Ⅱ) diethyldithiocarbamate (CuET) on the proliferation and apoptosis of hepatocellular carcinoma cells
and investigate the molecular mechanisms.
Methods
2
MTT assay was used to detect cell viability in the hepatocellular carcinoma HepG2 and SMMC-7721 cells treated with CuET at the concentrations of 0
0.01
0.05
0.1
0.5
1 or 2 μmol/L for 24 h. Then after the HepG2 and SMMC-7721 cells were treated with 2 μmol/L CuET for 0
3
6
9
12 or 24 h
MTT assay
soft agar assay and flow cytometry were used to determine cell viability
colony formation and cell apoptosis
respectively. And Western blotting was performed to detect the expression of apoptosis-related proteins
including cleaved-Caspase 9
cleaved-Caspase 3
cleaved-PARP1 and cytochrome C
and mitochondrial mitotic proteins
such as phospho-Drp1 (S637)
phospho-Drp1(S616)
and dynamin-related protein 1 (Drp1). Laser confocal scanning microscopy was carried out to observe the effect of 1 μmol/L Mdivi-1 pretreatment (a selective inhibitor of Drp1 mitochondrial translocation) for 2 h on the mitochondrial translocation of Drp1. Its effects on the apoptosis and expression levels of above proteins were also studied.
Results
2
Compared with the control cells (0 μmol/L)
CuET treatment showed inhibitory effects on the proliferation and colony formation
and inductive effect on the apoptosis in HepG2 and SMMC-7721 cells in dose- and time-dependent manners (all
P
<
0.01). Western blot assay indicated that CuET treatment led to cleavage/activation of Caspase 3 and Caspase 9
degradation of PARP
as well as release of cytochrome C from the mitochondria into the cytoplasm. CuET treatment also caused dephosphorylation and mitochondrial translocation of Drp1 (S637). Mdivi-1 pretreatment obviously blocked the mitochondrial translocation of Drp1
cleavage/activation of Caspase 3
release of cytochrome C
as well as cell apoptosis induced by CuET treatment.
Conclusion
2
CuET inhibits the proliferation and promotes apoptosis in hepatocellular carcinoma cells through dephosphorylation and mitochondrial translocation of Drp1.
关键词
Keywords
references
HIROKAWA F, HAYASHI M, ASAKUMA M, et al . Risk factors and patterns of early recurrence after curative hepatectomy for hepatocellular carcinoma[J ] . Surg Oncol, 2016, 25(1): 24-29. DOI:10.1016/j.suronc.2015.12.002.
BRAY F, FERLAY J, SOERJOMATARAM I, et al . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J ] . CA Cancer J Clin, 2018, 68(6): 394-424. DOI:10.3322/caac.21492.
COLLINS F S. Mining for therapeutic gold[J]. Nat Rev Drug Discov, 2011, 10(6): 397. DOI:10.1038/nrd3461.
WRIGHT C, MOORE R D. Disulfiram treatment of alcoholism[J]. Am J Med, 1990, 88(6): 647-655. DOI:10.1016/0002-9343(90)90534-k.
CVEK B. Nonprofit drugs as the salvation of the world's healthcare systems: the case of Antabuse (disulfiram)[J]. Drug Discov Today, 2012, 17(9/10): 409-412. DOI:10.1016/j.drudis.2011.12.010.
ILJIN K, KETOLA K, VAINIO P, et al . High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth[J ] . Clin Cancer Res, 2009, 15(19): 6070-6078. DOI:10.1158/1078-0432.ccr-09-1035.
CHEN D, CUI Q C, YANG H, et al . Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity[J ] . Cancer Res, 2006, 66(21): 10425-10433. DOI:10.1158/0008-5472.can-06-2126..
ZHA J, CHEN F L, DONG H J, et al . Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition[J ] . J Transl Med, 2014, 12(1): 1-9. DOI:10.1186/1479-5876-12-163..
SAFI R, NELSON E R, CHITNENI S K, et al . Copper signaling axis as a target for prostate cancer therapeutics[J ] . Cancer Res, 2014, 74(20): 5819-5831. DOI:10.1158/0008-5472.can-13-3527.
DUFOUR P, LANG J M, GIRON C, et al . Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study[J ] . Biotherapy, 1993, 6(1): 9-12. DOI:10.1007/bf01877380.
SKROTT Z, MISTRIK M, ANDERSEN K K, et al . Alcohol-abuse drug disulfiramtargets cancer via p97 segregase adaptor NPL4[J ] . Nature, 2017, 552(7684): 194-199. DOI:10.1038/nature25016..
ZHOU M, WANG H, ZENG X, et al . Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J ] . Lancet, 2019, 394(10204): 1145-1158. DOI:10.1016/s0140-6736(19)30427-1.
CHEN W Q, ZHENG R S, BAADE P D, et al . Cancer statistics in China, 2015[J ] . CA Cancer J Clin, 2016, 66(2): 115-132. DOI:10.3322/caac.21338.
WANG F S, FAN J G, ZHANG Z, et al . The global burden of liver disease: the major impact of China[J ] . Hepatology, 2014, 60(6): 2099-2108. DOI:10.1002/hep.27406.
FU J, WANG H. Precision diagnosis and treatment of liver cancer in China[J]. Cancer Lett, 2018, 412: 283-288. DOI:10.1016/j.canlet.2017.10.008.
VOGEL A, CERVANTES A, CHAU I, et al . Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J ] . Ann Oncol, 2018, 29: ⅳ238-ⅳ255. DOI:10.1093/annonc/mdy308.
European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI:10.1016/j.jhep.2018.03.019.
ESTAQUIER J, ARNOULT D. Inhibiting Drp1-mediated mitochondrial fission selectively prevents the release of cytochrome C during apoptosis[J]. Cell Death Differ, 2007, 14(6): 1086-1094. DOI:10.1038/sj.cdd.4402107.
BROOKS C, CHO S G, WANG C Y, et al . Fragmented mitochondria are sensitized to Bax insertion and activation during apoptosis[J ] . Am J Physiol-Cell Physiol, 2011, 300(3): C447-C455. DOI:10.1152/ajpcell.00402.2010.
WAI T, LANGER T. Mitochondrial dynamics and metabolic regulation[J]. Trends Endocrinol Metab, 2016, 27(2): 105-117. DOI:10.1016/j.tem.2015.12.001.
XU B, WANG S, LI R, et al . Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2[J ] . Cell Death Dis, 2017, 8(5): e2797. DOI:10.1038/cddis.2017.176..
SHAH O'BRIEN P, XI Y, MILLER J R, et al . Disulfiram (antabuse) activates ROS-dependent ER stress and apoptosis in oral cavity squamous cell carcinoma[J ] . J Clin Med, 2019, 8(5): 611. DOI:10.3390/jcm8050611.
KIM J Y, CHO Y, OH E, et al . Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer[J ] . Cancer Lett, 2016, 379(1): 39-48. DOI:10.1016/j.canlet.2016.05.026.
CHOI S A, CHOI J W, WANG K C, et al . Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid/rhabdoid tumors[J ] . Neuro-Oncol, 2015, 17(6): 810-821. DOI:10.1093/neuonc/nou305.
LOO T W. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism[J ] . J Natl Cancer Inst, 2000, 92(11): 898-902. DOI:10.1093/jnci/92.11.898.
SONG W, TANG Z, SHEN N, et al . Combining disulfiram and poly(l-glutamic acid)-cisplatin conjugates for combating cisplatin resistance[J ] . J Control Release, 2016, 231: 94-102. DOI:10.1016/j.jconrel.2016.02.039.
KESHAMOUNI V G, MICHAILIDIS G, GRASSO C S, et al . Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype[J ] . J Proteome Res, 2006, 5(5): 1143-1154. DOI:10.1021/pr050455t.